Long-Term Effects of Peptide Cycling in Bodybuilding

What long-term means for cyclical users

Bodybuilders who use growth hormone secretagogues rarely run them nonstop. The usual pattern is weeks on, a break, then another block, repeated for years, and no study has followed people through it. As of October 2026, the longest controlled human data in this class is a two-year trial of daily MK-677 in adults over 60, and the longest on repeated injections of a GH-releasing peptide is a 16-week hexarelin study.

The rest of the picture comes from short pharmacology studies, population data on natural IGF-1 levels, FDA safety reviews and forum reports. Each answers a narrower question than the one lifters are asking.

Does the response fade with repeated cycles?

Many users say a GHRH/GHRP combination such as Mod GRF 1-29 with ipamorelin feels strongest in the first weeks, mostly through better sleep and recovery, and that the effect seems weaker on later runs. Hexarelin has the strongest reputation for this. Lifters often describe it losing its effect within about a month.

The one human study that measured this directly is small but useful. Rahim and Shalet gave 12 healthy older adults hexarelin by subcutaneous injection twice daily for 16 weeks. The GH response (area under the curve) fell from 19.1 at baseline to 13.1 at week 1 and 10.5 at week 16, a drop of roughly 45%. Four weeks after the course ended, a repeat dose produced a response of 19.4, no different from baseline. The attenuation was partial, and it reversed with a month off.

MK-677 behaved differently. In the two-year trial by Nass and colleagues, 65 healthy adults aged 60-81 took 25 mg by mouth daily, and their GH and IGF-1 rose to the levels of healthy young adults. Exploratory two-year analyses confirmed the first-year results, so daily use didn't erase the effect over that period. Tolerance seems to depend on the compound, and nobody has run a comparable study of ipamorelin or GHRP-2 in young lifters.

Forum explanations for the fade usually point to desensitization of pituitary receptors, or to a rise in somatostatin, the hormone that brakes GH release. Both are plausible, but neither has been measured in people running repeated cycles. Simpler explanations fit too: the first change people notice, often deeper sleep, stands out more than later steady effects, and gray-market batches vary.

The CJC-1295 "GH bleed" claim

A common claim, which this page used to repeat, is that CJC-1295 with DAC replaces the natural GH pulse with a constant "bleed." The human data don't support that. In a 2006 study by Ionescu and Frohman, healthy men aged 20-40 received a single injection of 60 or 90 mcg/kg. Overnight blood sampling a week later showed that the frequency and size of GH pulses were unchanged. What rose was the floor between pulses: trough GH went up 7.5-fold, mean GH rose 46%, and IGF-1 rose 45%.

The DAC form still matters for cycling, for a different reason. In the trials by Teichman and colleagues, one injection raised GH 2- to 10-fold for 6 days or more and IGF-1 1.5- to 3-fold for 9-11 days (half-life 5.8-8.1 days), and after repeated doses IGF-1 stayed above baseline for up to 28 days. Those trials didn't study off-cycles, but the numbers suggest the first weeks of a break from the DAC form aren't much of a break.

Whether the raised trough pushes somatostatin up over months is unknown. Most forum users actually describe the no-DAC form, Mod GRF 1-29, which acts for a much shorter time. Our CJC-1295 profile explains how the two forms differ.

Blood sugar and insulin sensitivity

Growth hormone raises blood glucose and promotes lipolysis, and the pancreas answers with more insulin. That's normal physiology. The question for long-term users is what happens when GH stays raised for months at a time, cycle after cycle.

The best human data again come from the MK-677 trial. Fasting glucose rose by an average of 0.3 mmol/L (5 mg/dL), and insulin sensitivity fell. Those were healthy older adults on a daily oral compound, so the size of the effect in a 30-year-old lifter using injectable peptides is a guess. FDA's safety summary for GHRP-2 also mentions reports of increased insulin requirements, in patients rather than healthy users and without established causality.

Nobody has measured whether insulin sensitivity fully recovers during off-periods, or whether small changes add up across years of cycles.

Fluid retention, side effects and the heart

Side effects that fade within one cycle can come back with every new one. In the MK-677 trial, the most frequent were increased appetite that faded within a few months and transient, mild lower-leg swelling; cortisol also rose by 47 nmol/L on average. In the first CJC-1295 trial, 94% of participants had an adverse event after a single injection, mostly injection-site reactions. User reports for the GHRH/GHRP stack, summarized on our ipamorelin profile, center on water retention, numb or tingling hands, and tiredness.

Two heart-related signals come from sick or elderly populations, not lifters. FDA describes an unpublished Phase 2 trial of CJC-1295 in HIV lipodystrophy that ended after a participant had a fatal heart attack two hours after an 11th weekly dose; the attending physician blamed undiagnosed coronary disease. FDA also notes that a trial of MK-677 in patients recovering from hip fracture was stopped early for a possible congestive heart failure signal. Neither says much about healthy young users, because no one has studied that group.

IGF-1 and cancer risk

IGF-1 drives cell growth and survival, which is why it comes up in cancer research. Population studies link higher natural IGF-1 levels to modestly higher risk of some cancers. A 2004 meta-analysis of 21 studies in The Lancet found that people at the 75th percentile of IGF-1 had higher odds of prostate cancer (odds ratio 1.49) and premenopausal breast cancer (1.65) than people at the 25th. In UK Biobank, about 394,000 participants were followed for a mean of 6.9 years. Each 5 nmol/L of higher IGF-1 was linked to 8% higher colorectal and prostate cancer risk and 11% higher breast cancer risk, and the authors note that reverse causality can't be ruled out.

These are associations with natural IGF-1 levels, mostly within the normal range. They don't show that peptide-driven increases cause cancer, or that cycling protects anyone, but they can't be dismissed either. For CJC-1295 specifically, FDA's 2024 review noted signs of DNA damage in pituitary cells in nonclinical studies and said that, without carcinogenicity studies, pituitary hyperplasia and tumors can't be ruled out. The risk is theoretical but plausible, and the human data that would settle it don't exist.

What cycling can and can't do

The hexarelin study is the best evidence for planned breaks: the GH response recovered fully after four weeks off. Whether that applies to ipamorelin, GHRP-2 or the GHRH analogs hasn't been tested. Community guides commonly describe runs of 8-16 weeks followed by roughly a month off, or weekday-only schedules such as five days on and two off. We found no trial comparing these patterns. The schedules in our overview of peptide cycling protocols are community practice, not tested regimens.

Breaks may help with tolerance; it's less clear they help with the slower concerns. If cancer risk tracks total time at higher IGF-1, more weeks off would lower exposure, but that's an inference from population data, not a measured effect. Some community guides suggest long-time users scale back to the smallest amount that still changes their sleep or recovery, a reasonable idea that no one has tested. Stacking adds compounds and makes it harder to tell which one causes a side effect; our page on peptide stacking strategies covers the combinations users describe.

For tested athletes, cycling doesn't change the rules. As of October 2026, WADA's 2026 Prohibited List names CJC-1295, ipamorelin, GHRP-2, hexarelin and MK-677 under S2.2.4, prohibited at all times. None of these peptides is an approved medicine in the US, and FDA's 2024 review of CJC-1295 stated that its long-term safety profile in humans is unknown.

Blood markers long-term users track

Without long-term studies, blood work is how individual users and their doctors can see what's changing. These markers come up most often for repeated GH secretagogue use:

• IGF-1. The most direct readout of GH activity. In the CJC-1295 trials, IGF-1 went above the normal range at the highest dose (250 mcg/kg). Reference ranges fall with age.
• Fasting glucose and fasting insulin. Together they give HOMA-IR, an estimate of insulin resistance, which is where the MK-677 trial found a change.
• HbA1c. A roughly three-month average of blood sugar that confirms trends rather than catching them early.
• Lipid panel. In the MK-677 trial, LDL cholesterol fell slightly.
• Complete blood count and metabolic panel. General checks of blood cells and of kidney and liver function.

A pre-cycle test gives a baseline. Testing again late in a cycle and during a break would show whether values return to it, which is the central open question for cyclical use. We found no published clinical monitoring guidance for this kind of use, so these markers reflect common practice rather than a standard, and a physician is the right person to interpret them.

What we still don't know

• Whether GH responses to ipamorelin, GHRP-2 or Mod GRF 1-29 fade over repeated cycles the way hexarelin's did, and how long recovery takes.
• Whether glucose control returns fully during off-periods, or whether small changes accumulate over years.
• Whether years of intermittently raised IGF-1 change cancer risk in healthy adults.
• Whether the heart and fluid signals seen in sick or elderly trial participants show up in healthy long-term users.
• How much of the reported fade reflects the product rather than the body, since users rarely have independent confirmation of what is in a vial.